Toggle Main Menu Toggle Search

Open Access padlockePrints

Inhibiting 11β-hydroxysteroid dehydrogenase type 1 prevents stress effects on hippocampal synaptic plasticity and impairs contextual fear conditioning

Lookup NU author(s): Professor Brian WalkerORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes intracellular regeneration of corticosterone and cortisol, thereby enhancing glucocorticoid action. Inhibition of 11β-HSD1 reverses the deficits in cognition with aging, a state of elevated glucocorticoid levels. However, any impact of 11β-HSD1 inhibition during high glucocorticoid states in younger animals is unknown. Here we examined whether a single injection of the selective 11β-HSD1 inhibitor UE2316 modifies the effect of stress on hippocampal long-term potentiation and fear conditioning, a learning paradigm that is strongly modulated by glucocorticoids. We found that novelty stress suppresses hippocampal synaptic potentiation. This effect was completely prevented by administration of UE2316 one hour before stress exposure. A single injection of UE2316 also impaired contextual, but not tone-cue-fear conditioning. These observations suggest that local metabolism of glucocorticoids is relevant for the outcome of stress effects on hippocampal synaptic plasticity and contextual fear conditioning. Selective 11β-HSD1 inhibitors may be an interesting new approach to the prevention of trauma-associated psychopathology. © 2014 Elsevier Ltd. All rights reserved.

Publication metadata

Author(s): Sarabdjitsingh RA, Zhou M, Yau JLW, Webster SP, Walker BR, Seckl JR, Joels M, Krugers HJ

Publication type: Article

Publication status: Published

Journal: Neuropharmacology

Year: 2014

Volume: 81

Pages: 231-236

Print publication date: 01/06/2014

Online publication date: 01/02/2014

Acceptance date: 23/01/2014

ISSN (print): 0028-3908

ISSN (electronic): 1873-7064

Publisher: Elsevier Ltd


DOI: 10.1016/j.neuropharm.2014.01.042

PubMed id: 24495397


Altmetrics provided by Altmetric